Table 2.

Associations Between Admission MR‐proADM and Prognosis

Outcome	Univariate Model		Multivariable Model 1		Multivariable Model 2
	HR (95% CI)	P Value	HR (95% CI)	P Value	HR (95% CI)	P Value
30‐day all‐cause mortality	3.93 (2.51–6.14)	<0.0001	3.14 (1.86–5.33)	<0.0001	2.67 (1.01–7.11)	0.049
30‐day cardiovascular mortality	3.93 (2.51–6.14)	<0.0001	3.14 (1.86–5.33)	<0.0001	2.67 (1.01–7.11)	0.049
Long‐term all‐cause mortality	3.43 (2.67–4.41)	<0.0001	2.59 (1.91–3.52)	<0.0001	3.23 (1.97–5.29)	<0.0001
Long‐term cardiovascular mortality	3.64 (2.63–5.04)	<0.0001	3.06 (2.10–4.45)	<0.0001	3.17 (1.56–6.42)	0.002
Hospital admission for heart failure	3.45 (2.40–5.00)	<0.0001	3.17 (2.12–4.73)	<0.0001	2.71 (1.32–5.58)	0.007

Model 1 was adjusted for age and sex. Model 2 was adjusted additionally for age, sex, time since onset of symptoms, left ventricular ejection fraction, heart rate, estimated glomerular filtration rate, TIMI‐flow before primary PCI, anterior myocardial infarction, log2‐transformed peak concentrations of hs‐cTnT, and medical history of the following variables: diabetes mellitus, hypertension, history of smoking, previous myocardial infarction, previous stroke, and congestive heart failure. CI indicates confidence interval; HR, hazard ratio; hs‐cTnT, high‐sensitivity cardiac troponin T; MR‐proADM, midregional proadrenomedullin; PCI, primary percutaneous coronary intervention; TIMI‐flow, angiographic thrombolysis in myocardial infarction flow.